[{"orgOrder":0,"company":"Crossject","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Steroid","year":"2025","type":"Collaboration","leadProduct":"Hydrocortisone","moa":"||Glucocorticoid receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Crossject \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Crossject \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"St. Jude Children's Research Hospital","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Hematopoietic Stem Cell Transplant","moa":"||DNA","graph1":"Oncology","graph2":"Phase II","graph3":"St. Jude Children's Research Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrathecal","sponsorNew":"St. Jude Children's Research Hospital \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"St. Jude Children's Research Hospital \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"St. Jude Children's Research Hospital","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase II","graph3":"St. Jude Children's Research Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"St. Jude Children's Research Hospital \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"St. Jude Children's Research Hospital \/ AbbVie Inc"},{"orgOrder":0,"company":"Princess Maxima Center for Pediatric Oncology","sponsor":"Innovative Therapies for Children with Cancer Consortium | IBFM | Fight Kids Cancer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Decitabine","moa":"||DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Princess Maxima Center for Pediatric Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Princess Maxima Center for Pediatric Oncology \/ Innovative Therapies for Children with Cancer Consortium | IBFM | Fight Kids Cancer","highestDevelopmentStatusID":"7","companyTruncated":"Princess Maxima Center for Pediatric Oncology \/ Innovative Therapies for Children with Cancer Consortium | IBFM | Fight Kids Cancer"},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AVM Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"||Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Laboratoires Thea","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic","sponsorNew":"Laboratoires Thea \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Laboratoires Thea \/ Inapplicable"},{"orgOrder":0,"company":"Tolmar","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Agreement","leadProduct":"Hydrocortisone","moa":"||Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Tolmar","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tolmar \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Tolmar \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Citrine Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"||Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Citrine Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Citrine Medicine"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Citrine Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Partnership","leadProduct":"Hydrocortisone","moa":"||Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Citrine Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Citrine Medicine"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"||Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Inapplicable"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"||Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"||Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"EffRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"||Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Diurnal Group \/ EffRx Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ EffRx Pharmaceuticals"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Acquisition","leadProduct":"Hydrocortisone","moa":"||Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Diurnal Group \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"EffRx Pharmaceuticals","sponsor":"Diurnal Group","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"||Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"EffRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"EffRx Pharmaceuticals \/ Diurnal Group","highestDevelopmentStatusID":"15","companyTruncated":"EffRx Pharmaceuticals \/ Diurnal Group"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2025","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"||Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Opevesostat","moa":"||CYP11A1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Orion Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Orion Corporation"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Opevesostat","moa":"||CYP11A1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Orion Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Orion Corporation"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"||Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"||Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"||Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Inapplicable"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"||Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Inapplicable"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"||Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Diurnal Group \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"||Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"||Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Opevesostat","moa":"||CYP11A1","graph1":"Oncology","graph2":"Phase III","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orion Corporation \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Orion Corporation \/ Merck & Co"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"||Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ponatinib","moa":"||Bcr\/Abl fusion protein","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"St. Jude Children's Research Hospital","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"St. Jude Children's Research Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"St. Jude Children's Research Hospital \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"St. Jude Children's Research Hospital \/ AbbVie Inc"},{"orgOrder":0,"company":"Princess Maxima Center for Pediatric Oncology","sponsor":"Innovative Therapies for Children with Cancer Consortium | IBFM | Fight Kids Cancer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trametinib","moa":"||Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Princess Maxima Center for Pediatric Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Princess Maxima Center for Pediatric Oncology \/ Innovative Therapies for Children with Cancer Consortium | IBFM | Fight Kids Cancer","highestDevelopmentStatusID":"7","companyTruncated":"Princess Maxima Center for Pediatric Oncology \/ Innovative Therapies for Children with Cancer Consortium | IBFM | Fight Kids Cancer"},{"orgOrder":0,"company":"Princess Maxima Center for Pediatric Oncology","sponsor":"Innovative Therapies for Children with Cancer Consortium | IBFM | Fight Kids Cancer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"||Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Princess Maxima Center for Pediatric Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Princess Maxima Center for Pediatric Oncology \/ Innovative Therapies for Children with Cancer Consortium | IBFM | Fight Kids Cancer","highestDevelopmentStatusID":"7","companyTruncated":"Princess Maxima Center for Pediatric Oncology \/ Innovative Therapies for Children with Cancer Consortium | IBFM | Fight Kids Cancer"},{"orgOrder":0,"company":"Princess Maxima Center for Pediatric Oncology","sponsor":"Innovative Therapies for Children with Cancer Consortium | IBFM | Fight Kids Cancer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dasatinib","moa":"||Tyrosine-protein kinase ABL | Bcr\/Abl fusion protein | Platelet-derived growth factor receptor beta | Ephrin type-A receptor 2 | SRC | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Princess Maxima Center for Pediatric Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Princess Maxima Center for Pediatric Oncology \/ Innovative Therapies for Children with Cancer Consortium | IBFM | Fight Kids Cancer","highestDevelopmentStatusID":"7","companyTruncated":"Princess Maxima Center for Pediatric Oncology \/ Innovative Therapies for Children with Cancer Consortium | IBFM | Fight Kids Cancer"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Opevesostat","moa":"||CYP11A1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Orion Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Orion Corporation"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Opevesostat","moa":"||CYP11A1","graph1":"Oncology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Orion Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Orion Corporation"},{"orgOrder":0,"company":"St. Jude Children's Research Hospital","sponsor":"Karyopharm Therapeutics | AbbVie Inc | Gateway for Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"St. Jude Children's Research Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"St. Jude Children's Research Hospital \/ Karyopharm Therapeutics | AbbVie Inc | Gateway for Cancer Research","highestDevelopmentStatusID":"6","companyTruncated":"St. Jude Children's Research Hospital \/ Karyopharm Therapeutics | AbbVie Inc | Gateway for Cancer Research"},{"orgOrder":0,"company":"Andrew E. Place","sponsor":"AbbVie Inc | Servier | Children's Cancer Research Fund | University of Colorado, Denver | Boston Children's Hospital | Gateway for Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Andrew E. Place","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Andrew E. Place \/ AbbVie Inc | Servier | Children's Cancer Research Fund | University of Colorado, Denver | Boston Children's Hospital | Gateway for Cancer Research","highestDevelopmentStatusID":"6","companyTruncated":"Andrew E. Place \/ AbbVie Inc | Servier | Children's Cancer Research Fund | University of Colorado, Denver | Boston Children's Hospital | Gateway for Cancer Research"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"INSERM | Versailles Saint Quentin en Yvelines University | Universit\u00e9 Paris-Saclay | Paris 12 Val de Marne University | Commissariat A L'energie Atomique | Beckman Coulter | Lumedix | Elice | Biothelis","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"||NR3C1","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ INSERM | Versailles Saint Quentin en Yvelines University | Universit\u00e9 Paris-Saclay | Paris 12 Val de Marne University | Commissariat A L'energie Atomique | Beckman Coulter | Lumedix | Elice | Biothelis","highestDevelopmentStatusID":"1","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ INSERM | Versailles Saint Quentin en Yvelines University | Universit\u00e9 Paris-Saclay | Paris 12 Val de Marne University | Commissariat A L'energie Atomique | Beckman Coulter | Lumedix | Elice | Biothelis"},{"orgOrder":0,"company":"Faes Farma","sponsor":"Dynamic Science","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SPAIN","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"||Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Faes Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Rectal Ointment","sponsorNew":"Faes Farma \/ Dynamic Science","highestDevelopmentStatusID":"10","companyTruncated":"Faes Farma \/ Dynamic Science"},{"orgOrder":0,"company":"Medivir","sponsor":"Shijiazhuang Yuanmai Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Acyclovir","moa":"||DNA polymerase||Human herpesvirus 1 DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Medivir \/ Shijiazhuang Yuanmai Biotechnology","highestDevelopmentStatusID":"15","companyTruncated":"Medivir \/ Shijiazhuang Yuanmai Biotechnology"},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Apremilast","moa":"||PDE4","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Global Coalition for Adaptive Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Global Coalition for Adaptive Research \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Global Coalition for Adaptive Research \/ Inapplicable"},{"orgOrder":0,"company":"Scandinavian Critical Care Trials Group","sponsor":"Rigshospitalet | Copenhagen Trial Unit, Center for Clinical Intervention Research | University of Copenhagen | Aarhus University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"||Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scandinavian Critical Care Trials Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Scandinavian Critical Care Trials Group \/ Rigshospitalet | Copenhagen Trial Unit, Center for Clinical Intervention Research | University of Copenhagen | Aarhus University Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Scandinavian Critical Care Trials Group \/ Rigshospitalet | Copenhagen Trial Unit, Center for Clinical Intervention Research | University of Copenhagen | Aarhus University Hospital"},{"orgOrder":0,"company":"Tiohundra AB","sponsor":"Sahlgrenska University Hospital | Stockholm South General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Arginine Vasopressin","moa":"||Vasopressin receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tiohundra AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tiohundra AB \/ Sahlgrenska University Hospital | Stockholm South General Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Tiohundra AB \/ Sahlgrenska University Hospital | Stockholm South General Hospital"},{"orgOrder":0,"company":"Agnes","sponsor":"Direction G\u00e9n\u00e9rale de l'Offre de Soins | Laboratoires Thea","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"||Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Agnes","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Agnes \/ Direction G\u00e9n\u00e9rale de l'Offre de Soins | Laboratoires Thea","highestDevelopmentStatusID":"10","companyTruncated":"Agnes \/ Direction G\u00e9n\u00e9rale de l'Offre de Soins | Laboratoires Thea"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"18-F Fludeoxyglucose","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"Children's Oncology Group \/ National Cancer Institute"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Atopic Dermatitis Research Network | Rho, Inc | PPD","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Clobetasol","moa":"||Staphylococcus aureus load","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Atopic Dermatitis Research Network | Rho, Inc | PPD","highestDevelopmentStatusID":"7","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Atopic Dermatitis Research Network | Rho, Inc | PPD"},{"orgOrder":0,"company":"St. Jude Children's Research Hospital","sponsor":"Syndax Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Revumenib","moa":"||Menin\/Histone-lysine N-methyltransferase MLL","graph1":"Oncology","graph2":"Phase I","graph3":"St. Jude Children's Research Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"St. Jude Children's Research Hospital \/ Syndax Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"St. Jude Children's Research Hospital \/ Syndax Pharmaceuticals"},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"||Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Antares Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antares Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antares Pharma \/ Inapplicable"},{"orgOrder":0,"company":"TACL Consortium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Tagraxofusp","moa":"||Interleukin-3 receptor subunit alpha | Elongation factor 2","graph1":"Oncology","graph2":"Phase I","graph3":"TACL Consortium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TACL Consortium \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TACL Consortium \/ Inapplicable"},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"||Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Antares Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antares Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antares Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast International S\u00e0rl","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Diphenhydramine","moa":"||Alloreactive T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mesoblast International S\u00e0rl","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast International S\u00e0rl \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Mesoblast International S\u00e0rl \/ Inapplicable"},{"orgOrder":0,"company":"Vastra Gotaland Region","sponsor":"Swedish Society of Medicine | \u00c5ke Wibergs Stiftelse | Sahlgrenska University Hospital | Pilloxa","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"||Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Vastra Gotaland Region","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vastra Gotaland Region \/ Swedish Society of Medicine | \u00c5ke Wibergs Stiftelse | Sahlgrenska University Hospital | Pilloxa","highestDevelopmentStatusID":"1","companyTruncated":"Vastra Gotaland Region \/ Swedish Society of Medicine | \u00c5ke Wibergs Stiftelse | Sahlgrenska University Hospital | Pilloxa"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Crossject","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"||Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eton Pharmaceuticals \/ Crossject","highestDevelopmentStatusID":"15","companyTruncated":"Eton Pharmaceuticals \/ Crossject"},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"AVM0703","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"AVM Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVM Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AVM Biotechnology \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals for Hydrocortisyl
Details :
ODM-208 (or MK-5684) is an investigational oral, non-steroidal and selective inhibitor of the CYP11A1 enzyme discovered and developed by Orion for the treatment of hormone-dependent cancers, such as metastatic castration-resistant prostate cancer.
Details :
KHINDIVI (hydrocortisone) is a corticosteroid indicated as replacement therapy in pediatric patients 5 years of age and older with adrenocortical insufficiency.
Details :
ETON in-licensed commercialization rights to ZENEO® Hydrocortisone, a unique, and proprietary ready-to-use liquid formulation of hydrocortisone, for the US and Canadian markets.
Details :
ET-400 is Eton’s proprietary patented formulation of hydrocortisone oral solution. Company has submitted NDA for ET-400 use in endocrine system disorders.
Details :
ET-400 is Eton’s proprietary patented formulation of hydrocortisone oral solution. Company has submitted NDA for ET-400 use in endocrine system disorders.
Reset All
